The short version
- Why people research itLibido, hormonal signaling and reproductive / sexual function.
- What the evidence isA licensed drug with strong trial data for hyperprolactinemia and prolactinoma, where it reliably normalizes prolactin and shrinks tumors — outperforming bromocriptine in head-to-head trials.
- What to watchNew breathlessness, ankle swelling or a new heart murmur.
How Cabergoline works
Cabergoline is an ergot alkaloid. The ergoline scaffold is a rigid tetracyclic system that happens to present the same pharmacophore as several monoamines — so an ergoline drug is almost never selective for one receptor family, and cabergoline is not.
The intended target: the D2 receptor on the pituitary lactotroph. Prolactin is unique among pituitary hormones in being under tonic inhibition. Dopamine released from tuberoinfundibular neurons travels down the hypophyseal portal system and acts on D2 receptors on lactotrophs.
- Oral
Research on Cabergoline5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
A licensed drug with strong trial data for hyperprolactinemia and prolactinoma, where it reliably normalizes prolactin and shrinks tumors — outperforming bromocriptine in head-to-head trials.
Which is why those indications were restricted. But echocardiographic monitoring on long-term use is standard for a reason.
Correlative data
Used off-label for prolactin-related sexual dysfunction and alongside compounds that raise prolactin. Reported experience includes nausea and hypotension early, and mood changes including impulse-control effects in a minority — the latter is a documented dopaminergic class effect.
How the mechanism reads
A long-acting D2 dopamine receptor agonist. Dopamine is the physiological brake on prolactin, so agonizing D2 suppresses it.
MechanisticThe same D2 activity predicts the rest of the profile — nausea via the chemoreceptor trigger zone, hypotension, and the impulse-control effects that follow from dopaminergic signaling in reward pathways.
Mechanistic
Sources
- Mishra R, et al. A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas. Indian Journal of Endocrinology and Metabolism 2021 · PMID 35355923
- Cozzi R, et al. Italian Guidelines for the Management of Prolactinomas. Endocrine, Metabolic and Immune Disorders Drug Targets 2023 · PMID 37171003
- Cai X, et al. Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis. Chinese Neurosurgical Journal 2022 · PMID 35395837
- Steeds RP, et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Echo Research and Practice 2019 · PMID 30825409
- Hayes AG, et al. Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma. Endocrine Oncology 2023 · PMID 37434646
Cabergoline safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Heart valve disease, or pulmonary or retroperitoneal fibrosis, since ergot agonism of 5-HT2B scars valves.
- Uncontrolled hypertension, or pregnancy-related high blood pressure.
- Severe liver impairment, because cabergoline clearance is hepatic.
- Psychosis or past compulsive gambling or shopping.
- Low blood pressure or fainting episodes.
What’s expected
- Prolactin falls sharply because D2 agonism removes the pituitary brake release.
- Nausea, dizziness and drowsiness early on.
- Raised libido and testosterone if prolactin was high.
Watch for
- New breathlessness, ankle swelling or a new heart murmur.
- Compulsive urges such as gambling or shopping.
- Fainting when you stand, the D2 agonist hypotension pattern.
Labs that tell you it’s working
- Prolactin: the direct target, which should fall within days.
- Total & Free Testosterone: rises when excess prolactin stops suppressing the axis.
- Comprehensive Metabolic Panel: liver function, since cabergoline is hepatically cleared.
Long-acting ergoline D2 agonist; prolactin suppression by design, valvulopathy from 5-HT2B agonism on cardiac valves. PMID 37434646 PMID 30825409 PMID 35355923
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “Low T? Rule Out the Reversible Causes First” panel, explained
Cabergoline FAQ4 common questions
- Is Cabergoline approved for human use?
- Cabergoline is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Cabergoline researched for?
- Libido, hormonal signaling and reproductive / sexual function.
- Which labs show whether it's doing anything?
- Prolactin; Total & Free Testosterone; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Cabergoline: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



